ライフサイエンスコーパス: microL

1 cted as low as 1pg/microL (3.43x10(-1)copies/microL).

2 od cell count, 6890/microL (5700/microL-8030/microL).

3 tile of the background population, 835 cells/microL).

4 ls/microL (interquartile range, 38-191 cells/microL).

5 l (i.e. 0.8 fmol in used sample volume of 10 microl).

6 idental drop was 29 microL (min-max of 20-33 microL).

7 nts at ART initiation were low (99-172 cells/microL).

8 he Y2 receptor antagonist BIIE0246 (2 nmol/2 microl).

9 with different concentrations of ZIKAV (PFU/microL).

10 e density was 6946/microL (range, 40-436 450/microL).

11 rolled (median CD4(+) T-cell count, 34 cells/microL).

12 te blood cell count greater than 20000 cells/microL.

13 V-coinfected patients with counts >350 cells/microL.

14 ring a sustained CD4 T-cell count >500 cells/microL.

15 the median CD4(+) T-cell count was 503 cells/microL.

16 ls with CD8(+) T-cell counts of >/=500 cells/microL.

17 with a CD4(+) T-cell count of >/= 200 cells/microL.

18 was 748 (interquartile range, 481-930) cells/microL.

19 lute NK-cell counts remained below 200 cells/microL.

20 log10 copies/mL and CD4 count was 390 cells/microL.

21 with a CD4(+) T-cell count of 500-1500 cells/microL.

22 ns of a pathogen matrix, as few as 18 spores/microL.

23 with those who achieved CD4 count >200 cells/microL.

24 tients starting ART with CD4 count <50 cells/microl.

25 ors for not achieving a CD4 count >200 cells/microL.

26 ts with CD4 counts between 350 and 500 cells/microL.

27 with CMV-IRR had a CD4 count of >/=50 cells/microL.

28 edian CD4 count was 430 (IQR, 190-620) cells/microL.

29 dian CD4(+) T-lymphocyte count was 471 cells/microL.

30 count at presentation to care was 452 cells/microL.

31 icroL, and 28-fold with parasitemia >100 000/microL.

32 hite blood cell (WBC) count was 37.7 x 10(9)/microL.

33 ly among women with CD4 counts of <350 cells/microL.

34 nadir CD4 count was 142 (IQR, 42-240) cells/microL.

35 in the patient specimens was 1.05 e4 copies/microL.

36 gh specificity and detection limit of 4.57IU/microl.

37 HAV cDNA with a limit of detection of 6.4fg/microL.

38 ART), and the median CD4 count was 149 cells/microL.

39 hough the specimen had >3000 red blood cells/microL.

40 s with a parasite density range of 40-54 059/microL.

41 w-up time with a CD4 T-cell count >500 cells/microL.

42 cells/microL maintained counts >/=200 cells/microL.

43 ed when CD4 T-cell counts fell to <550 cells/microL.

44 microL, 95.6% maintained counts >/=200 cells/microL.

45 CD1 mice by injecting collagenase VII-S (0.5 microL, 0.06 U) into the basal ganglia.

46 als with a CD8(+) T-cell count of <500 cells/microL 1 year after cART initiation had an increased mor

47 in patients with an initial count >350 cells/microL (1.8%) and higher in those with an initial count

48 Detection limits of 87 genomic units (GU) microL(-1) and 26GUmicroL(-1) for Legionella spp. and Le

49 microL(-1) in the linear range of 100-500 ng microL(-1) and stability of about 120 days.

50 ng(-1) cm(-2), detection limit of ~21.70 ng microL(-1) in the linear range of 100-500 ng microL(-1)

51 range of detection from 1microL(-1) to 10(5)microL(-1) target molecules (20 to 2 million targets), m

52 ly reduced monitoring were rarely <200 cells/microL: 1.1% of the tests conducted when minimal monitor

53 holds: white blood cell count less than 5000/microL, 10% (95% CI, 4% to 16%) (to convert to 109 per l

54 atients with nadir CD4 cell count >200 cells/microL (140 per 100 000 person-years [95% CI, 80-247]).

55 to 36%); absolute neutrophil count >/=10000/microL, 18% (95% CI, 10% to 25%) (to convert to x 109 pe

56 ty with nadir white blood cell counts >2.7 K/microL 2 weeks after HSCT and recovery by 4 weeks.

57 ilis DNA samples and detection limit of 10pg/microL (2.2x10(3)copies/microL) was achieved.

58 those with an initial count of 200-249 cells/microL (23.1%).

59 -cell count at ART initiation (112-178 cells/microL), 24-week ART suppressive efficacy (78%), second-

60 y by 0.001); white blood cell count >/=15000/microL, 27% (95% CI, 18% to 36%); absolute neutrophil co

61 crofa (pork) meat was detected as low as 1pg/microL (3.43x10(-1)copies/microL).

62 ients, with a mean CD4 increase of 156 cells/microL (4.6%).

63 6 U/L); and for white blood cell count, 6890/microL (5700/microL-8030/microL).

64 multiply by 0.001); and platelets <100 x 103/microL, 7% (95% CI, 2% to 12%) (to convert to x 109 per

65 ed at a CD4 lymphocyte cell count <200 cells/microL (80% coverage and 96% effectiveness) prevents 20%

66 or white blood cell count, 6890/microL (5700/microL-8030/microL).

67 h an initial CD4 cell count of 300-349 cells/microL, 95.6% maintained counts >/=200 cells/microL.

68 counts stabilized at approximately 900 cells/microL (95th percentile of the background population, 83

69 l application of capsaicin (10 microg/ml, 50 microl), a selective stimulant for TRPV1 receptors, in a

70 ve persons with CD4 cell counts </=500 cells/microL, a higher threshold than was previously recommend

71 thresholds for white blood cell count (11600/microL), absolute neutrophil count (4100/microL), and pl

72 5 (15%) did not reach a CD4 count >200 cells/microL after 3 years of suppression.

73 for failure to achieve CD4 count >200 cells/microL after 3 years of sustained viral suppression and

74 Individuals with CD4 </=200 cells/microL after 3 years of viral suppression had substantia

75 on was 261 cells/microL before and 363 cells/microL after the 2009 guideline change (P < .0001).

76 PCR), to parasitemia limits of 0.02 parasite/microL and 0.78 parasite/microL in PfLDH- and PfIDEh-bas

77 lities to detect E. coli and S. aureus in 10 microL and 100 microL batch microbial cocktail samples.I

78 and median CD4 count was 161 (101-188) cells/microL and 167 (135-1353) cells/microL, respectively.

79 showed detection limits of 100-200 parasites/microL and 200-400 parasites/microL, respectively.

80 nd current CD4(+) T-cell counts of 175 cells/microL and 242 cells/microL, respectively.

81 D8 T-cell counts of 565 (IQR, 435-742) cells/microL and 727 (IQR, 530-991) cells/microL respectively,

82 t diagnosis, median CD4 T-cell count was 387/microL and 94% of patients were treated with cART.

83 h baseline platelet count <150 000 platelets/microL and albuminemia <35 g/L) died from multiorgan fai

84 within reaction volumes of approximately 0.7 microL and at concentrations down to 2mM.

85 ed index patients with CD4 counts >250 cells/microL and contacts of index patients who were not HIV-i

86 Median CD4(+) count was 655 cells/microL and HIV load was <50 copies/mL in 89% of subjects

87 ted patients with CD4 cell counts >300 cells/microL and HIV/HCV-coinfected patients with counts >350

88 tion limit of LAMP-SPR sensing was 10 copies/microl and LAMP-SPR sensing system showed a good selecti

89 -infected patients with CD4 cell counts <350/microL and microbiologically proved tuberculosis.

90 tients who had a CD4 T-cell count <100 cells/microL and negative serum cryptococcal antigen initiatin

91 Sample volume was 10 microL and total assay time under 3 h.

92 te blood cell count greater than 20000 cells/microL and total bilirubin level greater than 10 mg/dL a

93 -infected adults with CD4 count </=200 cells/microL and tuberculosis, randomized to initiate ART eith

94 icipants had CD4 cell counts of >/=500 cells/microL and were not taking antiretroviral therapy.

95 overy was 6.4 weeks for neutrophils (>/=1000/microL) and 10.6 weeks for platelets (>/=100 x 10(9)/L).

96 rs for incomplete CD4 recovery (</=200 cells/microL) and Cox regression to identify associations with

97 s/microL; interquartile range, 318-585 cells/microL) and HIV-uninfected individuals with latent tuber

98 sociated with faster CD4 decline (<350 cells/microl) and this association was stronger after accounti

99 of cell samples and antibiotic reagents (<6 microL), and (4) improved portability through the implem

100 600/microL), absolute neutrophil count (4100/microL), and platelet count (362 x 103/microL) were iden

101 ith a limit of detection (LoD) of 3.9nM, 5pg/microl, and 10(3)CFU/ml, respectively.

102 Median CD4 count was 333 cells/microL, and 23% of patients had HIV infection classified

103 a increased 11-fold with parasitemia >20 000/microL, and 28-fold with parasitemia >100 000/microL.

104 Median CD4 count was 310 cells/microL, and 40% had undetectable HIV-1 load.

105 were male, median CD4(+) count was 561 cells/microL, and brachial FMD was 4.2%.

106 nfected individuals have <500 CD4(+) T cells/microL, and CD4(+) T cells in lymphoid tissues remain se

107 t at enrollment was 520 (IQR, 392-719) cells/microL, and median nadir CD4 count was 142 (IQR, 42-240)

108 median age was 37 years, CD4 count 321 cells/microL, and viral load 4.5 log10 copies/mL.

109 failure were mean age 38 years, mean CD4 173/microL, and WT virus prevalence 20%; genotype cost was $

110 IV, longer exposure to CD4 counts <200 cells/microL, and, to a lesser extent, higher levels of high-s

111 6.3), to have leukocyte counts >20 000 cells/microL (aOR, 4.6), and to have lymphocyte counts >10 000

112 and to have lymphocyte counts >10 000 cells/microL (aOR, 7.2) (all P </= .05).

113 1 cells/microL at presentation and 152 cells/microL at ART initiation.

114 itiation had CSF white cell count (WCC) >/=5/microL at day 14 (58% vs 40%; P = .047), after a median

115 T-cell count increased from 325 to 379 cells/microL at diagnosis and from 178 to 360 cells/muL at ART

116 ainly driven by participants with CSF WCC <5/microL at meningitis diagnosis: 28% (10/36) of such pers

117 an estimated CD4 count in 2002 was 251 cells/microL at presentation and 152 cells/microL at ART initi

118 mL) for >3 years with CD4 count </=200 cells/microL at start of the suppressed period.

119 t E. coli and S. aureus in 10 microL and 100 microL batch microbial cocktail samples.Isignal response

120 an CD4 count at ART initiation was 261 cells/microL before and 363 cells/microL after the 2009 guidel

121 ed >/=14 years with >/=1 CD4 count of >/=200 microL between 1998 and 2010 were included.

122 tagonist BIBO3304 trifluoroacetate (2 nmol/2 microl), but not by the Y2 receptor antagonist BIIE0246

123 ion was defined as CD4 decline to <350 cells/microL by 2 years postinfection.

124 sons in the early ART group had CSF WCC >/=5/microL by day 14, compared with 0% (0/27) in the deferre

125 defined by a white blood cell count >100,000/microL, caused by leukemic cell proliferation.

126 controlled trial in HIV+ with CD4(+) T cells/microL (CD4) >/= 200 randomized to receive the 23-valent

127 , for patients with a CD4(+) cell count >500/microL, clinicians would defer ART if patients did not f

128 emonstrated a high sensitivity of 1.6 copies/microL, comparable to off-chip detection using conventio

129 e and with a CD4 cell count of less than 200/microL compared with 7- to 12-year-old participants (30%

130 ts with a poor outcome (8408 [12 465] copies/microL) compared with patients with a good outcome (1842

131 cytopenia (platelet count, <50,000 platelets/microL), compared with those without malaria (adjusted o

132 etection ranged from 3.7 to 15 femtograms/10 microL, depending on the species.

133 eeks, CD4(+) T-cell decline showed a 40-cell/microL difference (P = .03) in the intention-to-treat po

134 ding angles of less than 10 degrees for a 35 microL droplet.

135 s to promote mixing of small liquid volumes (microL droplets) through a combination of coalescence an

136 of maintaining CD4 cell counts >/=200 cells/microL during continuous HIV suppression.

137 by the limit of detection (as low as 0.1 PFU/microL, equivalent to copy number of 4.9) in spiked swab

138 le the percentage with CD4 counts <200 cells/microL fell from 31% to 11%.

139 Using 100 microl finger-prick blood samples, the Cepheid Xpert HIV

140 ving had a CD4(+) T-cell count of >500 cells/microL for >18 months (OR, 0.88; 95% CI, .82-.94; P = .0

141 sustained CD4(+) T-cell count of >500 cells/microL for >18 months are independently and significantl

142 tients on cART, with CD4 counts >/=500 cells/microL for at least 2 years and viral load </=500 copies

143 pecimens with CD4 T-cell counts </=100 cells/microL for cryptococcal antigen (CrAg) using the CrAg la

144 AIDS patients with a CD4 count </=100 cells/microL for cryptococcal infection.

145 .65pM for the complementary ssDNA and 6.94fg/microL for viral cDNA.

146 sedentary individuals in large volume (>/=10 microL) for on-demand and in situ analysis has limited o

147 oL (interquartile range [IQR], 197-475 cells/microL) for the CSB+ group, and 341 cells/microL (IQR, 2

148 B+ group, and 341 cells/microL (IQR, 213-464/microL) for the RUSF group.

149 to swiftly resolve and measure sharp (20 25 microL full-width-half-maximum) chromatography peaks.

150 control cerebrospinal fluid (flow rate 0.25 microl/h, 14 days).

151 10 000 copies/mL and/or CD4 count <200 cells/microL had lower rates of seroconversion rates.

152 individuals with baseline CD4+ >/= 500 cells/microL had plaque risk not statistically different from

153 RT who do not achieve a CD4 count >200 cells/microL have substantially increased long-term mortality.

154 antiretrovirals; median CD4 count: 489 cells/microL; HCV treatment naive 29%; HCV genotype 1/2/3/4: 5

155 =28 weeks' gestation, CD4 count >/=200 cells/microL, hemoglobin level >/=7 g/L) in 19 health centers

156 count was 8.15 (95% CI, -.13 to 16.43) cells/microL higher in the atazanavir group.

157 This method, which required as low as 10ng/microL (i.e., 50ng) of purified EGFR protein, also enabl

158 CD4 cell counts fell to <200 cells/microL in 5.7% of monoinfected and 11.1% of coinfected p

159 stinfection, respectively, and to <500 cells/microL in 69%, 79%, and 81% at equivalent timepoints.

160 CD4 cell counts fell to <200 cells/microL in 7.4% patients, and the proportion was lower in

161 at diagnosis of CMV retinitis was <50 cells/microL in 73.4% of cases.

162 of patients, whereas CD4 counts went >/=500/microl in 75%.

163 -naive patients with CD4 counts </=100 cells/microL in Cape Town, South Africa.

164 ts of 0.02 parasite/microL and 0.78 parasite/microL in PfLDH- and PfIDEh-based assays, respectively.

165 ca (median CD4 count 102, 213, and 172 cells/microl in South Africa, Europe, and North America, respe

166 stained CD4 T-cell restoration to >500 cells/microL in the majority of study participants.

167 had B-cell clonal counts above 500 cells per microL, including 3 with 1693 to 2887 cells per microL;

168 culosis and baseline CD4 counts </=125 cells/microL initiating ART.

169 ian CD4 cell count at baseline was 339 cells/microL (interquartile range [IQR], 197-475 cells/microL)

170 nts were included (median CD4 count 53 cells/microL (interquartile range [IQR], 22-132); 16 (27%) die

171 an CD4 count and VL at switch were 177 cells/microL (interquartile range [IQR], 77-263) and 4.3 log10

172 A slight drop of 130 cells/microL (interquartile range, -160 to 410 cells/muL) in t

173 nts' median CD4(+) T-cell count was 89 cells/microL (interquartile range, 38-191 cells/microL).

174 oma diagnosis among IRIS cases was 173 cells/microL (interquartile range, 73-302), and 48% had suppre

175 virus coinfected (median CD4 count 16 cells/microL [interquartile range, 6-40]).

176 nfected (median CD4+ T-cell count, 522 cells/microL; interquartile range, 318-585 cells/microL) and H

177 ls/microL) for the CSB+ group, and 341 cells/microL (IQR, 213-464/microL) for the RUSF group.

178 [IQR], 3096-23 120 copies/mL) and 100 cells/microL (IQR, 77-171 cells/microL), respectively.

179 ting from negative to positive values at 700 microL L(-1) [CO2] and mycorrhizal effects on photosynth

180 ceratophorum, RBio increased from 180 to 390 microL L(-1) and further increases in [CO2] caused RBio

181 igh-CO2 (1,000 microL L(-1)) or low-CO2 (150 microL L(-1)) conditions.

182 spp. was fully acclimated to high-CO2 (1,000 microL L(-1)) or low-CO2 (150 microL L(-1)) conditions.

183 ngi across a broad [CO2] gradient (180-1,000 microL L(-1)).

184 nt CD4 cell counts (median, 230 vs 383 cells/microL), lipid levels (mean [SD] total cholesterol level

185 cted patients with initial counts >350 cells/microL maintained counts >/=200 cells/microL.

186 Thailand (mean baseline CD4 count, 188 cells/microL; mean viral load, 5.4 log10 copies/mL) was follow

187 , 35 years; median CD4 cell count, 151 cells/microL; median VL, 5.0 log10 copies/mL; 58% non-B subtyp

188 , these factors made it possible for the 100-microL MFC to achieve among the highest areal and volume

189 Pumping flow rates from 5.3 to 40 microL min(-1) under different rotating speeds of the TE

190 The mean volume of an accidental drop was 29 microL (min-max of 20-33 microL).

191 < .001 and 100.8 microL/min +/- 24.3 vs 4.8 microL/min +/- 1.0; P < .001, respectively) were signifi

192 id clearance (47.5 microL/min +/- 5.6 vs 7.3 microL/min +/- 2.7; P < .001 and 100.8 microL/min +/- 24

193 s 7.3 microL/min +/- 2.7; P < .001 and 100.8 microL/min +/- 24.3 vs 4.8 microL/min +/- 1.0; P < .001,

194 and para-aminohippuric acid clearance (47.5 microL/min +/- 5.6 vs 7.3 microL/min +/- 2.7; P < .001 a

195 decreased to 0.67 (0.07; 95% CI, 0.49-0.86) microL/min at 4 weeks (P = .001, unpaired t test).

196 at 1 week was 2.46 (0.36; 95% CI, 1.55-3.44) microL/min but decreased to 0.67 (0.07; 95% CI, 0.49-0.8

197 tic eyes without retinopathy, and 44.4 (8.3) microL/min in age-matched healthy eyes.

198 the eyes with DR but without DME, 40.1 (7.7) microL/min in the diabetic eyes without retinopathy, and

199 The mean (SD) TRBF was 28.0 (8.5) microL/min in the eyes with DME, 48.8 (13.4) microL/min

200 microL/min in the eyes with DME, 48.8 (13.4) microL/min in the eyes with DR but without DME, 40.1 (7.

201 oid infusion of 1-2 ml of fresh blood at 200 microl/min over cortical sulci caused clusters of spread

202 een the CERA (3.39 [0.76; 95% CI, 1.43-5.48] microL/min) and pediatric (4.52 [0.52; 95% CI, 3.19-5.95

203 nd pediatric (4.52 [0.52; 95% CI, 3.19-5.95] microL/min) GDDs (P = .28, unpaired t test) at 4 weeks w

204 bited a wide range of TRBF from 31.1 to 75.0 microL/min, with the distribution being highly skewed.

205 However, free Kin values (microl/min/g brain) for the sham (0.265+/-0.034) and PCA

206 owlesi malaria included parasitemia >100 000/microL (n = 18), jaundice (n = 20), respiratory distress

207 CD4 decline to <350 cells/microL occurred in 31%, 44%, and 55% of women at 1, 2, a

208 te blood cell count of more than 20000 cells/microL (odds ratio, 3.4; 95% CI, 1.2-9.5; P = .02) and t

209 ometric detection was realized by spiking 10 microL of a hydroquinone (HQ) solution into 40 microL of

210 After intravenous injection of 2x200 microL of a perfluorocarbon on day 19 and 20 (n=9) after

211 croL of a hydroquinone (HQ) solution into 40 microL of buffer solution containing hydrogen peroxide.

212 Moreover, because only 1 microl of liquid is required, as little as 1.2 fmol of t

213 , as few as 10 rickettsial organisms per 100 microl of lysed blood sample can be analyzed within 60 m

214 hen, the acceptor solution was mixed with 20 microL of NaOH solution (0.1 M) and analyzed using scree

215 ble, extremely sensitive and requires just 1 microl of patient serum (or even less) to measure PSA an

216 allows low sample and reagent consumption (3 microL of reaction), portability, ease-of-use, and rapid

217 nd puncture, vital signs were measured, and1 microL of saline with or without 3 nmol orexin-A was inf

218 or descending (LAD) coronary artery, and 100 microL of saline, hydrogel alone, or hydrogel+25 microg

219 in 50 minutes has been demonstrated, with 20 microl of sample consumption, inclusive of dead volume i

220 onding to 15 copies of the target gene in 50 microL of sample, can be successfully detected and relia

221 ication of miRNA extracted directly from 500 microL of serum had limited sensitivity and specificity.

222 Without perturbing the eyeball, 3 microL of tear fluid was sampled from the marginal conju

223 icrol to 1 microl reaction master mix with 1 microl of template DNA in each reaction.

224 of protease in up to 40 samples with only 1 microl of volume required for each sample.

225 aches achieved MCF-7 cell capture from </=10 microL of whole blood with efficiencies greater than 85%

226 DBS samples (equivalent to approximately 12 microl of whole blood).

227 n simultaneously detect EBOV and SUDV in 200 microL of whole blood.

228 pes Virus (KSHV) in a fingerprick volume (50 microL) of PBS, plasma, and artificial saliva samples fo

229 nced, had CD4+ lymphocyte count >/=200 cells/microL or >/=14%, and plasma HIV-1 RNA suppression on on

230 3.86-40.33), and platelet count >10(5) cells/microL (OR, 7.44; 95% CI, 3.51-15.78) were associated wi

231 -99, 100-199, 200-349, 350-499, >/=500 cells/microL) overall and separately according to time since s

232 {IQR}, -18 to 43] vs 68 [IQR, 24-131] cells/microL, P = .002).

233 te densities (GMPD) 306 968/microL vs 92 642/microL, P = .028) and were younger (median age: 24 month

234 s 2% of person-time with CD4 cell count <200/microL; P < .001 for each comparison).

235 antial blood depletion (409.0 vs 877.8 cells/microL; P < .001).

236 ignificantly higher CD4 T-cell count (>/=200/microL; P < .03) and a lower CMV load (P < .004) was obs

237 CD4(+) cell counts (median, 275 vs 213 cells/microL; P = .005) at VF than those who changed.

238 0 Sprague-Dawley rats, 2 microg rhTSG-6 in 5-microL phosphate-buffered saline (PBS) or the same volum

239 into an acidic aqueous acceptor solution (20 microL) placed inside the lumen of a hollow fiber.

240 ith an elevated mtDNA level (>/=3,200 copies/microl plasma) had increased odds of dying within 28 d o

241 oventricular (icv) infusion of NPY (1 nmol/2 microl) prolonged retention of non-social (object) memor

242 a limit of detection (LOD) in the lowest ng/microL range) which matches with their typical concentra

243 hin about 30 min with a sample volume in the microl range.

244 Geometric mean parasite density was 6946/microL (range, 40-436 450/microL).

245 xtending ART eligibility to CD4 </=500 cells/microL ranged from $237 to $1691/DALY compared to 2010 g

246 mix was performed starting at 10 microl to 1 microl reaction master mix with 1 microl of template DNA

247 2) cells/microL and 727 (IQR, 530-991) cells/microL respectively, and viral suppression for 5.4 (IQR,

248 /mL) and 100 cells/microL (IQR, 77-171 cells/microL), respectively.

249 of the latter 2 groups were 150 and 93 cells/microL, respectively, and the median viral loads were 14

250 h CD4 counts <350, 350-499, and >/=500 cells/microL, respectively, whereas it was 10% (95% CI, 0%-21%

251 1-188) cells/microL and 167 (135-1353) cells/microL, respectively.

252 ell counts of 175 cells/microL and 242 cells/microL, respectively.

253 0-200 parasites/microL and 200-400 parasites/microL, respectively.

254 Blood droplets (35 microL) roll through the tubes at 15 degrees sliding ang

255 ncreased risk (>/=500 to 350-500 CD4 T cells/microL: RR, 1.29 [95% CI, 1.21-1.37] and <100 cells/micr

256 RR, 1.29 [95% CI, 1.21-1.37] and <100 cells/microL: RR, 7.4 [95% CI, 6.87-8.02]).

257 ected BoNT/A endoprotease activity in 50-100 microl serum samples from all patients (11/11) with type

258 (interquartile range [IQR], 47-386) bacteria/microL sputum, which was 5.1% (IQR, 2.4%-11%) the concen

259 for patients with CD4 cell-counts <100 cells/microl starting ART 1) no screening or prophylaxis (stan

260 um A), 201-350 (stratum B), and </=200 cells/microL (stratum C).

261 ased immuno-PCR assays to detect <1 parasite/microL suggests that improvements of bound antibody sens

262 Diluted bevacizumab was delivered using 300 microL syringes with 5/16-inch, 30-gauge fixed needles.

263 icroL with those whose counts were <50 cells/microL, the KS risk was halved in South Africa (aHR, 0.5

264 roL, including 3 with 1693 to 2887 cells per microL; the clone accounted for nearly all their circula

265 tion master mix was performed starting at 10 microl to 1 microl reaction master mix with 1 microl of

266 ected patients with a CD4 count </=100 cells/microL to detect and treat early infection.

267 of "HIV infected with a CD4 count <100 cells/microL" to the EORTC host criteria be validated.

268 etric mean parasite densities (GMPD) 306 968/microL vs 92 642/microL, P = .028) and were younger (med

269 ence = 4; P = .01), and CD4 count <200 cells/microL (vs >/=500) was associated with a younger age at

270 ving had a CD4(+) T-cell count of >500 cells/microL was 18.4 months at the time of a HR-HPV-negative

271 ents who enrolled with CD4 levels >350 cells/microL was 88.2% and mortality was 2.5%.

272 years, a CD8(+) T-cell count of >1500 cells/microL was associated with increased non-AIDS-related mo

273 ection limit of 10pg/microL (2.2x10(3)copies/microL) was achieved.

274 ighest quartile of WBC counts (>/=6500 cells/microL) was associated with increased CV events (OR 4.3;

275 luid (CSF) pleocytosis (>5 white blood cells/microL) was common (81%).

276 posed to a prototype AirFloss delivering 115 microL water at a maximum exit velocity of 60 m/sec in a

277 CD4 T-cell counts between 101 and 400 cells/microL were eligible.

278 RT was initiated at a CD4 count >/=200 cells/microL were estimated using Joint United Nations Program

279 Median CD8 counts/microL were higher in HIV-positive/CMV-positive patients

280 rculosis patients with CD4 counts <350 cells/microL were included; tuberculosis blood cultures were p

281 itive patients with a CD4 count </=250 cells/microL were infected with tuberculosis, compared to 22%

282 losis patients with a CD4 count </=250 cells/microL were less likely to be infected with tuberculosis

283 ne VL <30 000 copies/mL and CD4 >/=350 cells/microL were randomized to start open-label LPV/r 400/100

284 es/mL and CD4(+) T-cell counts of >350 cells/microL were randomly assigned to the vaccine or placebo

285 iagnosis with CM and a CD4 count </=50 cells/microL were significantly associated with CrAg positivit

286 g a nadir CD4(+) T-cell count of </=100 cell/microL were the only statistically significant predictor

287 (4100/microL), and platelet count (362 x 103/microL) were identified in models that had areas under t

288 iral therapy, with CD4(+) T-cell counts <800/microL, were given either NR100157 or an isocaloric and

289 d a limit of detection (LOD) of 3.4x10(6)EVs/microL when anti-CD81 and anti-CD9 were selected as capt

290 0 years (mean CD4(+) T-cell count, 360 cells/microL) who continued to smoke lost 6.7 years and 6.3 ye

291 RNA and DNA of 25 microL whole blood from 46 individuals from Burkina Faso

292 intaining CD4+ T cell counts above 500 cells/microL with 4 cycles or fewer over a period of two years

293 ts with current CD4 cell counts >/=700 cells/microL with those whose counts were <50 cells/microL, th

294 s; or white blood cell count >/=15 000 cells/microL within 1 day of positive test), severe outcome (i

295 d women progressed to a CD4 count <350 cells/microL within 2 years of infection.

296 drome defined by low CD4 T-cell counts (<300/microL) without evidence of HIV infection or other known

297 n treatment guidelines (CD4 count <500 cells/microL) would require most individuals to start antiretr

298 amisole and 5489 (IQR, 192-25 848) parasites/microL x hour in controls (P = .25).

299 terquartile range [IQR], 0-28 025) parasites/microL x hour in patients treated with levamisole and 54

300 ol vs active, -68 +/- 15 vs -28 +/- 16 cells/microL/year).